Literature DB >> 16539280

Sustained remission of lupus nephritis.

C E H Barber1, L Geldenhuys, J G Hanly.   

Abstract

The aim of this study was to describe the clinical course of patients with lupus nephritis (LN) who attain a sustained remission (SR) and identify predictors of SR. A retrospective study of patients with biopsy-proven LN were followed for up to 10 years. SR was defined as normal renal function, urine protein <0.5g/day, and an inactive urine sediment without significant immunosuppressive maintenance therapy for no less than three years. Control patients had LN but did not fulfill the criteria for SR. Data was collected at diagnosis of LN (T0), at onset of remission (T1), and at final follow-up (T2). A total of 35 patients were identified, 16 with a SR of LN and 19 controls, with a mean +/- SD follow-up of 126.4 +/- 8.5 months. Remission of LN was achieved following 37.7 +/- 6.8 months of therapy. At diagnosis (T0) the WHO classification of nephritis, activity and chronicity scores of renal biopsies were comparable in the two groups. At final follow-up (T2), the mean estimated creatinine clearance for the SR group was significantly higher than in controls (P = 0.009) and disease activity (SLEDAI scores) was lower (P = 0.002). Cumulative damage (SDI scores) in the SR group did not increase after patients entered remission (P = 0.250), whereas the mean SDI score in the control group increased significantly (P = 0.014) even when renal variables were excluded (P = 0.016). Multivariate analysis revealed that female gender (P = 0.023), older age (P = 0.034), higher nonrenal SLEDAI scores (P = 0.016) at the time of diagnosis of LN and absence of azathioprine (P = 0.010) were predictive of SR. It was concluded that remission of LN occurs in a substantial proportion of systemic lupus erythematosus (SLE) patients and may be sustained without maintenance immunosuppressive therapy. It is associated with a significantly slower accrual of both renal and non-renal damage over the ensuing seven years.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16539280     DOI: 10.1191/0961203306lu2271oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Leticia Hachuel; Gabriela Boggio; Daniel Wojdyla; Virginia Pascual-Ramos; Enrique R Soriano; Verónica Saurit; Fernando S Cavalcanti; Renato A Guzman; Marlene Guibert-Toledano; Maria J Sauza Del Pozo; Mary-Carmen Amigo; Magaly Alva; Maria H Esteva-Spinetti; Bernardo A Pons-Estel
Journal:  Rheumatology (Oxford)       Date:  2012-03-02       Impact factor: 7.580

3.  Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis.

Authors:  W W Xiong; J B Boone; L Wheless; C P Chung; L J Crofford; A Barnado
Journal:  Lupus       Date:  2019-06-12       Impact factor: 2.911

4.  Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort.

Authors:  G J Pons-Estel; G S Alarcón; P I Burgos; L Hachuel; G Boggio; D Wojdyla; R Nieto; A Alvarellos; L J Catoggio; M Guibert-Toledano; J Sarano; L Massardo; G M Vásquez; A Iglesias-Gamarra; L T Lavras Costallat; N A Da Silva; J L Alfaro; I Abadi; M I Segami; G Huerta; M H Cardiel; B A Pons-Estel
Journal:  Lupus       Date:  2013-07-15       Impact factor: 2.911

5.  Inactive disease and remission in childhood-onset systemic lupus erythematosus.

Authors:  Rina Mina; Marisa S Klein-Gitelman; Angelo Ravelli; Michael W Beresford; Tadej Avcin; Graciela Espada; B Anne Eberhard; Laura E Schanberg; Kathleen M O'Neil; Clovis A Silva; Gloria C Higgins; Karen Onel; Nora G Singer; Emily von Scheven; Lisa F Imundo; Shannen Nelson; Edward H Giannini; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

6.  Value of a complete or partial remission in severe lupus nephritis.

Authors:  Yiann E Chen; Stephen M Korbet; Robert S Katz; Melvin M Schwartz; Edmund J Lewis
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 8.237

Review 7.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Authors:  Alina Dima; Ciprian Jurcut; François Chasset; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-14       Impact factor: 5.346

8.  When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis: A Narrative Review.

Authors:  Gabriella Moroni; Giulia Frontini; Claudio Ponticelli
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-23       Impact factor: 8.237

9.  Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER).

Authors:  María Galindo-Izquierdo; Esther Rodriguez-Almaraz; José M Pego-Reigosa; Francisco J López-Longo; Jaime Calvo-Alén; Alejandro Olivé; Antonio Fernández-Nebro; Víctor Martinez-Taboada; Paloma Vela-Casasempere; Mercedes Freire; Francisco J Narváez; José Rosas; Mónica Ibáñez-Barceló; Esther Uriarte; Eva Tomero; Antonio Zea; Loreto Horcada; Vicenç Torrente; Iván Castellvi; Joan Calvet; Raúl Menor-Almagro; María A Aguirre Zamorano; Enrique Raya; Elvira Díez-Álvarez; Tomás Vázquez-Rodríguez; Paloma García de la Peña; Atusa Movasat; José L Andreu; Patricia Richi; Carlos Marras; Carlos Montilla-Morales; Blanca Hernández-Cruz; José L Marenco de la Fuente; María Gantes; Eduardo Úcar; Juan J Alegre-Sancho; Javier Manero; Jesús Ibáñez-Ruán; Manuel Rodríguez-Gómez; Víctor Quevedo; José Hernández-Beriaín; Lucía Silva-Fernández; Fernando Alonso; Sabina Pérez; Iñigo Rúa-Figueroa
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.